UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB/A
(X) Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the annual period ended JUNE 30, 2002
( ) Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from _____________ TO ______________
For the fiscal year ended June 30, 2002
Commission file number 0-21271
SANGUI BIOTECH INTERNATIONAL, INC.
(Exact name of small business issuer as specified in its charter)
Colorado 84-1330732
(State or other jurisdiction of (IRS Employer Identification Number)
incorporation or organization)
1508 Brookhollow Drive, Suite 354 92705
-----
Santa Ana, CA 92705 (Zip Code)
(Address of principal executive offices)
Issuer's telephone number, including area code (714) 429-7807
Securities registered under Section 12(g) of the Exchange Act:
Common Stock, no par value
--------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report on Form 10-KSB/A to be signed on its
behalf by the undersigned hereunto duly authorized.
SANGUI BIOTECH INTERNATIONAL, INC.
Date: October 17, 2002 /s/ Wolfgang Barnikol
-----------------------------------
Wolfgang Barnikol
President and Director
PART I
------
ITEM 4. Submission of matters to a vote of security holders
No matter was submitted to a vote of the Company's security holders during the
fourth quarter covered by this Report.
The Company encourages its shareholders to put forward shareholder proposals to
be submitted to a vote of security holders in the course of a shareholders'
meeting to be held in the first half of calendar year 2003. Shareholder
proposals should arrive at the company's offices in Santa Ana, California, or
Witten, Germany, no later than November 11, 2002. Shareholder proposals arriving
later than this date will be adjourned to be submitted to a subsequent
shareholders' meeting.
CERTIFICATION PURSUANT TO
18 U.S.C.SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Sangui BioTech International, Inc. (the
"Company") on Form 10-KSB/A the period ended June 30,2002, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"),the
undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.
Date: October 17, 2002 /s/ Wolfgang Barnikol
---------------------------
Wolfgang Barnikol
President and Director
CERTIFICATION
The undersigned, Prof. Dr. Dr. W. Barnikol, Chief Executive Officer and Chief
Financial Officer, certifies that:
1. I have reviewed this annual report on Form 10-KSB/A of Sangui
Biotech International, Inc.
2. Based on my knowledge, this annual report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of circumstances under which such
statements were made, not misleading with respect to the period covered by this
annual report; and
3. Based on my knowledge, the financial statements, and other
financial information included in this annual report, fairly present in all
material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this annual report.
Date: October 17, 2002 By: /s/ W. Barnikol
---------------------------
Prof. Dr. Dr. W. Barnikol,
Chief Executive Officer and
Chief Financial Officer